: The AMEDEO Literature Guide

Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription

Articles published in Br J Haematol
Retrieve available abstracts of 359 articles:
HTML format

Single Articles

October 2026

KISLOVA M, Dmitrieva E, Naumova E, Pochtar M, et al
Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype.
Br J Haematol. 2026;209:1664-1672.
PubMed Abstract available

KUNADT D, Zukunft S, Rollig C, Metzelder S, et al
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study.
Br J Haematol. 2026;209:1783-1796.
PubMed Abstract available

PALMIERI R, Piciocchi A, Soddu S, Frigeni M, et al
Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.
Br J Haematol. 2026;209:1735-1745.
PubMed Abstract available

LIU R, Li B, Zhang J, Xu W, et al
Multiparameter flow cytometry versus droplet digital polymerase chain reaction for monitoring measurable residual disease in paediatric fusion gene-positive acute myeloid leukaemia.
Br J Haematol. 2026;209:1562-1573.
PubMed Abstract available

MURAYAMA E, Kawai T, Yamato G, Shiba N, et al
Multiomics analysis focusing on genome-wide DNA methylation in paediatric acute promyelocytic leukaemia.
Br J Haematol. 2026;209:1586-1597.
PubMed Abstract available

TIZRO P, Aldoss I, Wang X, Kwak LW, et al
B-cell activating factor receptor expression in B-lymphoblastic leukaemia: Flow cytometric analysis and implications for targeted therapy.
Br J Haematol. 2026;209:1530-1537.
PubMed Abstract available

GAO J, Qiu H, Tong Y, Huang C, et al
Venetoclax-enhanced reduced-intensity conditioning in older patients aged >/=55 years with high-risk myeloid malignancies undergoing allogeneic peripheral blood stem cell transplantation: A phase II study.
Br J Haematol. 2026;209:1773-1782.
PubMed Abstract available

September 2026

ROSEN N, Rodriguez-Real G, Vom Stein AF, Schreurs LD, et al
Reduced colony-stimulating factor 1 receptor expression in myeloid cells has limited impact on chronic lymphocytic leukaemia progression.
Br J Haematol. 2026;209:939-952.
PubMed Abstract available

YANG Y, Tang Y, Yang K, Zhang Y, et al
CCAAT/enhancer-binding protein alpha basic leucine zipper in-frame insertion/deletion (CEBPA bZIP-InDel-inf) defines a favourable-prognosis subgroup in CEBPA-mutated acute myeloid leukaemia.
Br J Haematol. 2026;209:1136-1145.
PubMed Abstract available

CHAN WY, Al-Yousuf H, Lam HPJ, Leong S, et al
Real-world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia: A UK single-centre experience.
Br J Haematol. 2026;209:1386-1390.
PubMed Abstract available

SHIMIZU K, Saito MK, Maringe C, Miyazaki Y, et al
Socioeconomic inequality in treatment of acute myeloid leukaemia (AML) in England, 2015-2022: A population-based study.
Br J Haematol. 2026;209:1128-1135.
PubMed Abstract available

LIU Q, Wang X, Fan J, Zheng Y, et al
DHX15 affects AML1-ETO9a splicing together with HNRNPL, RBM33 in AML1-ETO-positive acute myeloid leukaemia.
Br J Haematol. 2026;209:964-977.
PubMed Abstract available

KHAN A, Gajendra S, Rai S, Thakral D, et al
Leukaemic stem cell burden enhances prognostic precision in the non-adverse European LeukemiaNet risk group of acute myeloid leukaemia.
Br J Haematol. 2026;209:1119-1127.
PubMed Abstract available

DUMINUCO A, Leotta D, Allegra A, Caracciolo D, et al
Real-world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience.
Br J Haematol. 2026;209:1010-1019.
PubMed Abstract available

PLAYA-ALBINYANA H, Giro A, Pineyroa JA, Araujo-Ayala F, et al
Scaffold-free three-dimensional culture of chronic lymphocytic leukaemia preserves B-T-cell cross-talk and enables drug response profiling.
Br J Haematol. 2026;209:953-963.
PubMed Abstract available

RUI M, Cheung YT, Zhang H, Wei Q, et al
Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost-effectiveness analysis.
Br J Haematol. 2026;209:1146-1157.
PubMed Abstract available

August 2026

HERMANSEN JU, Yin Y, Tjonnfjord GE, Mato AR, et al
Evolution of the drug sensitivity landscape of chronic lymphocytic leukaemia.
Br J Haematol. 2026;209:469-479.
PubMed Abstract available

INFANTE JB, Aguiar E, Sa I, Marques I, et al
Improved real-world outcomes of patients with acute promyelocytic leukaemia treated with first-line arsenic trioxide in specialized centres in Portugal through a 24/7 phone-based referral.
Br J Haematol. 2026;209:804-808.
PubMed Abstract available

GUPTA G, Podolsky S, Liu N, Cheung MC, et al
Frailty and health resource utilization in 5450 adults with acute myeloid leukaemia: A population-based study from Ontario, Canada.
Br J Haematol. 2026;209:601-609.
PubMed Abstract available

CONNERTY P, Colgan JN, El-Najjar F, Henry E, et al
The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.
Br J Haematol. 2026;209:491-502.
PubMed Abstract available

JIMENEZ-MIRA C, Tovar N, Martinez-Cibrian N, Gonzalez-Calle V, et al
Cesni-cel (ARI0002h) in ultra-high-risk multiple myeloma with plasma cell leukaemia or central nervous system involvement.
Br J Haematol. 2026;209:610-620.
PubMed Abstract available

LI R, Yao Y, Yang D, Mao L, et al
Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyrib
Br J Haematol. 2026;209:642-652.
PubMed Abstract available

BOBERG E, Lubking A, Lennmyr EB, Dietrich CE, et al
Central nervous system involvement and relapse in adult acute lymphoblastic leukaemia-a population-based analysis in 2007-2022.
Br J Haematol. 2026;209:589-600.
PubMed Abstract available

WANG H, Xue J, Yan W, Gao Y, et al
Identification of GSE1 as a PAX5 fusion partner and characterization of PAX5 fusion signature in B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2026;209:480-490.
PubMed Abstract available

ISHIDA H, Okamoto Y, Sakaguchi H, Arai Y, et al
Transplantation outcomes in patients with Down syndrome-associated acute lymphoblastic leukaemia: Implications for treatment intensity and the use of novel therapies.
Br J Haematol. 2026;209:632-641.
PubMed Abstract available

July 2026

IRIYAMA N, Takahashi N, Fujimaki K, Ono T, et al
Reattempt of tyrosine kinase inhibitor discontinuation after maintenance therapy with ponatinib in patients with chronic myeloid leukaemia in the chronic phase: Result of the Japan Adult Leukemia Study Group RE-STOP219 study.
Br J Haematol. 2026 Jul 9. doi: 10.1111/bjh.70678.
PubMed Abstract available

ZHOU J, Kui X, Huang D, Zhang X, et al
AKT inhibitor capivasertib reverses EVI1-driven resistance to venetoclax in acute myeloid leukaemia.
Br J Haematol. 2026;209:84-95.
PubMed Abstract available

BHATIA P, Sharun S, Palla S, Brady SW, et al
Acquired thiopurine resistance and mismatch repair aberrations in paediatric B-cell acute lymphoblastic leukaemia relapse: A real-world data integrating mutational signatures, clones and clinical thiopurine dosing patterns.
Br J Haematol. 2026;209:54-62.
PubMed Abstract available

FERRARA F
Azacitidine-venetoclax in unfit acute myeloid leukaemia: One size does not fit all.
Br J Haematol. 2026;209:391-392.
PubMed Abstract available

RAMPOTAS A, Naylor-Layland G, Brown C, Alabdulkarim A, et al
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.
Br J Haematol. 2026;209:160-171.
PubMed Abstract available

ZHANG ZX, Zhang L, Lu AD, Zhang LP, et al
Clinicogenetic characteristics and outcomes of children with NUP98-rearranged acute myeloid leukaemia: A single-centre cohort study of 32 cases.
Br J Haematol. 2026;209:172-179.
PubMed Abstract available

TODA Y, Jo T, Arai Y, Harada K, et al
Impact of CD34(+) cell dose on outcomes of related allogeneic PBSCT in adult AML patients.
Br J Haematol. 2026;209:210-221.
PubMed Abstract available

KATSIMIGAS A, Werling M, Frederiksen CM, Vainer N, et al
Effects of chronic lymphocytic leukaemia (CLL)-directed therapy on diffuse large B-cell lymphoma (DLBCL) type Richter transformation compared to de novo DLBCL in a nationwide cohort.
Br J Haematol. 2026 Jul 1. doi: 10.1111/bjh.70651.
PubMed Abstract available

June 2026

ITONAGA H, Fukushima T, Kato K, Muranushi H, et al
Improvements over time in survival after post-transplant relapse of adult T-cell leukaemia/lymphoma and trends of salvage therapy in a real-world experience.
Br J Haematol. 2026 Jun 15. doi: 10.1111/bjh.70631.
PubMed Abstract available

CHRISTENSEN LM, Simonsen MR, Jensen JF, Kristensen DT, et al
Improved survival with fludarabine-based therapies in mixed phenotype acute leukaemia: A population-based study using the WHO 2022 classification.
Br J Haematol. 2026;208:2104-2112.
PubMed Abstract available

May 2026

CHENG Q, Zhu Y, Sheng K, Zhou J, et al
Long-term outcomes after allogeneic versus autologous haematopoietic stem cell transplantation for T-lymphoblastic lymphoma.
Br J Haematol. 2026 May 24. doi: 10.1111/bjh.70581.
PubMed Abstract available

ALLSUP DJ, Cairns DA, Samy EF, Duley L, et al
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab.
Br J Haematol. 2026;208:1596-1607.
PubMed Abstract available

GEORGE A, Rolf E, Domeradzka M, Ribeiro S, et al
Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants.
Br J Haematol. 2026;208:1584-1595.
PubMed Abstract available

KALAMPALIKA F, Jimenez-Pompa A, Sanchez-Lanzas R, Patel B, et al
Chemotherapy-driven expression of WNT ligands in bone marrow stromal cells contributes to chemoresistance in acute lymphoblastic leukaemia.
Br J Haematol. 2026;208:1572-1583.
PubMed Abstract available

COWELL JK, Fang X, Mori SF, Hu T, et al
An oncogenic, truncated FGFR1 variant cooperates with SPFQ/NONO to regulate gene transcription in FGFR1-driven leukaemia.
Br J Haematol. 2026;208:1564-1571.
PubMed Abstract available

SCOTT AP, Lo A, Xia Y, Thompson K, et al
Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy.
Br J Haematol. 2026;208:1692-1703.
PubMed Abstract available

COSTA A, Scalzulli E, Carmosino I, Bisegna ML, et al
Very long-term outcomes of chronic-phase chronic myeloid leukaemia patients treated with imatinib: A 25-year real-world cohort study.
Br J Haematol. 2026;208:1669-1678.
PubMed Abstract available

MCILROY G, Carpenter B, Hough R, James B, et al
Haematopoietic stem cell transplantation outcomes for teenage and young adult patients with acute leukaemia: A British Society of Blood and Marrow Transplantation and Cellular Therapy registry study.
Br J Haematol. 2026;208:1745-1757.
PubMed Abstract available

CLAUDIANI S, Metelli S, Khan A, Hannah G, et al
Introducing a prognostic score for successful treatment-free remission in chronic myeloid leukaemia.
Br J Haematol. 2026;208:1660-1668.
PubMed Abstract available

YAMAMOTO C, Yamaguchi T, Honda S, Tominaga R, et al
Cost-effectiveness of blinatumomab as post-remission therapy in adults with measurable residual disease-negative, Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2026;208:1679-1691.
PubMed Abstract available

GROLL AH, Cesaro S, Alten J, Attarbaschi A, et al
Invasive yeast infection in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.
Br J Haematol. 2026;208:1846-1849.
PubMed Abstract available

KIM DH, Park SY, Cho H, Byun JM, et al
Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML.
Br J Haematol. 2026;208:1724-1733.
PubMed Abstract available

April 2026

VALCARCEL B, Utsunomiya A, Otsuka M, Miyahara M, et al
Distribution of adult T-cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.
Br J Haematol. 2026 Apr 15. doi: 10.1111/bjh.70494.
PubMed Abstract available

JEBARAJ BMC, Stilgenbauer S
Short and complex-Telomeres and genomes in CLL.
Br J Haematol. 2026;208:1503-1504.
PubMed Abstract available

DESAI N, Althobaiti M, Chen C, Al-Shaibani E, et al
Improved early transplant outcomes with reduced-dose PTCy and low-dose ATG in matched unrelated donor allogeneic transplantation for acute myeloid leukaemia.
Br J Haematol. 2026;208:1359-1368.
PubMed Abstract available

ERIKSEN JVN, de Pietri S, Rathe M, Hasle H, et al
Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.
Br J Haematol. 2026;208:1339-1346.
PubMed Abstract available

TIAN Z, Deng Z, Han F, Yu L, et al
An AI-based IHC quantification technique for assisting in the differentiation of MCL from CLL/SLL.
Br J Haematol. 2026;208:1287-1295.
PubMed Abstract available

KOMORI T, Kawai T, Okuno Y, Tsujimoto S, et al
Identification of cellular hierarchy in paediatric acute myeloid leukaemia: The Japan Children's Cancer Group trial (JCCG AML-12).
Br J Haematol. 2026;208:1252-1262.
PubMed Abstract available

BIDET A, Laharanne E, Dos Santos M, De Grande AC, et al
Optical genome mapping detects cryptic high-risk and targetable abnormalities in adult AML.
Br J Haematol. 2026;208:1232-1239.
PubMed Abstract available

MONAGHAN L, Bunschoten RP, Bittencourt-Silvestre J, Park T, et al
Selective small molecule targeting of KDM4 as a therapeutic strategy to reduce proliferation of acute myeloid leukaemia.
Br J Haematol. 2026;208:1240-1251.
PubMed Abstract available

LEE YW, Chiang CJ, Lin YC, Tzeng HE, et al
Second primary malignancies in Asian chronic lymphocytic leukaemia patients: A Taiwan Cancer Registry Study.
Br J Haematol. 2026;208:1278-1286.
PubMed Abstract available

DAI X, Wu Z, Zhang W, Chen S, et al
DHCR7 drives AML development through the IL6/JAK2/STAT3 signalling pathway.
Br J Haematol. 2026;208:1263-1277.
PubMed Abstract available

CRESPO-GARCIA E, Quero-Dotor C, Noguera-Castells A, Sancho-Vila L, et al
Epigenetic silencing and pharmacological inhibition of EIF5A2 foster venetoclax sensitivity in acute myeloid leukaemia.
Br J Haematol. 2026;208:1437-1442.
PubMed Abstract available

March 2026

MACPHAIL A, Loke J, Houston BL, Dendle C, et al
Prevention and management of febrile neutropenia in acute myeloid leukaemia and higher risk myelodysplastic syndrome: An international survey of current practice.
Br J Haematol. 2026;208:981-991.
PubMed Abstract available

FLEISCHMANN M, Hansen O, Voigtlander D, Bechwar J, et al
Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations.
Br J Haematol. 2026;208:905-915.
PubMed Abstract available

VERBEEK MWC, Sanders MA, Grashof DGB, Hoogenboezem RM, et al
The impact of scaRNA12 deregulation on p53-mediated cellular stress response in B-cell precursor acute lymphoblastic leukaemia.
Br J Haematol. 2026;208:883-896.
PubMed Abstract available

BRECCIA M, Giai V, Rosso T, Pregno P, et al
Risk factors and reasons for switching from front-line therapy in the Italian chronic myeloid leukaemia network: A cohort study.
Br J Haematol. 2026;208:974-980.
PubMed Abstract available

BOUDRY A, Chevillon F, Marceau-Renaut A, Braun T, et al
Assessment of measurable residual disease in ovarian tissue collected for fertility preservation in patients in remission from acute myeloid leukaemia: A pilot study.
Br J Haematol. 2026;208:897-904.
PubMed Abstract available

GU J, Wang J, Liu L, Zhang Y, et al
Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2026;208:954-964.
PubMed Abstract available

February 2026

YEUNG DT, Grigg AP, Reynolds J, Branford S, et al
The PINNACLE study: A multicentre phase II trial of nilotinib in combination with pegylated interferon-alpha2b in newly diagnosed chronic phase chronic myeloid leukaemia.
Br J Haematol. 2026;208:599-607.
PubMed Abstract available

JIN H, Guo Z, Zhu L, Huang F, et al
Integration of genomic and clinical variables improves the prediction of myelodysplastic syndromes to acute myeloid leukaemia transformation and prognosis.
Br J Haematol. 2026;208:524-533.
PubMed Abstract available

PETERS DT, Nicolet D, Madanat YF, Gonzalez-Lugo J, et al
Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium.
Br J Haematol. 2026;208:589-598.
PubMed Abstract available

WANG LY, Gao HT, Fu Q, Jiang Q, et al
Decoding the molecular drivers of TP53-mutant acute myeloid leukaemia: Clinical implications and prognostic insights.
Br J Haematol. 2026;208:579-588.
PubMed Abstract available

KYNNING MK, Westerberg E, Forsell L, Creignou M, et al
Comorbidities and mutations including single- and multihit TET2 mutations in relation to outcome in chronic myelomonocytic leukaemia-A population-based study.
Br J Haematol. 2026;208:514-523.
PubMed Abstract available

YAO CY, Hsu CL, Yang YT, Tien FM, et al
Genomic and transcriptomic characterization of acute myeloid leukaemia with IL3RA overexpression: Prognostic and therapeutic implications revisited.
Br J Haematol. 2026;208:503-513.
PubMed Abstract available

LEE BJ, Griffin SP, Doh J, Quach A, et al
Venetoclax combined with cladribine, idarubicin, cytarabine (CLIA-VEN) results in higher remission rates over conventional 7 + 3 chemotherapy without increased toxicity in newly diagnosed acute myeloid leukaemia.
Br J Haematol. 2026;208:570-578.
PubMed Abstract available

LIST J, Sollier E, Brown-Burke F, Kelly K, et al
Genocopy of EVI1-AML with paraneoplastic diabetes insipidus: PRDM16 overexpression by t(1;2)(p36;p21) and enhancer hijacking.
Br J Haematol. 2026;208:498-502.
PubMed Abstract available

KRISTENSEN DT, Simonsen MR, Roug AS, Marcher CW, et al
Outcomes among non-Western immigrant patients and Danish-born patients with acute myeloid Leukaemia: A Danish population-based cohort study.
Br J Haematol. 2026;208:564-569.
PubMed Abstract available

January 2026

YI S, Cao J, Feng R, Zhou K, et al
A comprehensive analysis of pirtobrutinib in Chinese patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Results from the phase 3 study BRUIN CLL-321.
Br J Haematol. 2026 Jan 22. doi: 10.1111/bjh.70334.
PubMed Abstract available

UENO T, Yoshimitsu M, Sameshima M, Nagano T, et al
Clinical features and incidence of central nervous system involvement in patients with adult T-cell leukaemia/lymphoma.
Br J Haematol. 2026 Jan 5. doi: 10.1111/bjh.70301.
PubMed Abstract available

TAN Y, Zhao X, Suo X, Bai G, et al
Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study.
Br J Haematol. 2026;208:189-199.
PubMed Abstract available

XU Q, Wang L, Hu S, Liao N, et al
Risk factors for DIC in paediatric APL: Insights from the CCLG-APL 2016 study.
Br J Haematol. 2026;208:200-209.
PubMed Abstract available

DUPONT M, Derouault P, Pascal V, Dmytruk N, et al
CLL-like stereotyped BCRs are equally produced in young and old healthy adults, share features of public clonotypes and may be stuck at a pre-germinal centre stage.
Br J Haematol. 2026;208:106-115.
PubMed Abstract available

WU LX, Liao MY, Zhao MY, Yan N, et al
Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia.
Br J Haematol. 2026;208:170-178.
PubMed Abstract available

HERMANS SJF, Versluis J, van Werkhoven ED, van Norden Y, et al
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.
Br J Haematol. 2026;208:179-188.
PubMed Abstract available

SHANMUGANATHAN N, Grigg A
A critical review of management of allogeneic transplant-eligible adults with Ph+ acute lymphoblastic leukaemia.
Br J Haematol. 2026;208:39-53.
PubMed Abstract available

December 2025

KIRK A, James B, Feltbower RG, Mushtaq T, et al
Bone mineral density and vertebral fractures in teenage and young adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma: A report from the British OsteoNecrosis Study (BONES).
Br J Haematol. 2025 Dec 18. doi: 10.1111/bjh.70286.
PubMed Abstract available

TEFFERI A, Patnaik MM
Chronic myelomonocytic leukaemia.
Br J Haematol. 2025;207:2280-2282.
PubMed Abstract available

NISCOLA P
Peripheral blood profiling of azacitidine's hypomethylation: Advancing precision medicine in juvenile chronic myelomonocytic leukaemia.
Br J Haematol. 2025;207:2661-2662.
PubMed Abstract available

CHEN EY, Dickman PW, Di Mari F, Dahlen T, et al
Empirical and projected economic burden of chronic myeloid leukaemia in Sweden from 2015 to 2030: A population-based study.
Br J Haematol. 2025;207:2441-2450.
PubMed Abstract available

BARRETT N, Gruber TA, Miyamura T, Duguid A, et al
Infant acute lymphoblastic leukaemia-Progress from worldwide clinical efforts.
Br J Haematol. 2025;207:2246-2260.
PubMed Abstract available

BUCHBINDER N, Michel V, Dalissier A, Kleinschmidt K, et al
Outcomes after a second allogeneic haematopoietic stem cell transplant for relapsed paediatric acute myeloid leukaemia improved over time: A study from the EBMT Paediatric Diseases Working Party.
Br J Haematol. 2025;207:2496-2506.
PubMed Abstract available

LILIENTHAL I, Tao S, Nilsson C, Leonard E, et al
Addition of hydroxyurea (hydroxycarbamide) enhances the efficacy of fludarabine/cytarabine-based salvage regimens against acute myeloid leukaemia.
Br J Haematol. 2025;207:2462-2474.
PubMed Abstract available

JEN WY, Tang G, Kugler E, Croden J, et al
MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia.
Br J Haematol. 2025;207:2451-2461.
PubMed Abstract available

QUIST-PAULSEN P, Horvei L, Dalgaard J, Moksnes M, et al
Improved outcomes in elderly patients with acute lymphoblastic leukaemia using a paediatric-based protocol-A prospective study.
Br J Haematol. 2025;207:2434-2440.
PubMed Abstract available

XAGORARI M, Marmarinos A, Doganis D, Nikita M, et al
NEAT1 lncRNA overexpression results in short-term progression and poor treatment outcome in childhood B-ALL.
Br J Haematol. 2025;207:2475-2485.
PubMed Abstract available

November 2025

BERTOLI D, Giupponi C, Rossi G, D'Adda M, et al
ET occurring in NPM1-mutated AML during molecular complete remission: A further potential evolution of a complex disease.
Br J Haematol. 2025;207:2153-2157.
PubMed Abstract available

METZLER M, Branford S, Hijiya N, Sakamoto K, et al
An old leukaemia in young patients-Genetic characteristics of paediatric chronic myeloid leukaemia.
Br J Haematol. 2025;207:1782-1788.
PubMed Abstract available

HILLS RK
Seeing something new or with new eyes?
Br J Haematol. 2025;207:2231-2232.
PubMed Abstract available

DAM M, Centanni M, Centanni D, Friberg LE, et al
Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study.
Br J Haematol. 2025;207:1920-1929.
PubMed Abstract available

BOUDRY A, Goursaud L, Lebon D, Dumezy F, et al
Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia.
Br J Haematol. 2025;207:1953-1961.
PubMed Abstract available

YING S, Yang L, Zhang L, Hong R, et al
The role of CBFbeta::MYH11 fusion gene in acute lysis pneumopathy: A dual impact on risk and prognosis.
Br J Haematol. 2025;207:1944-1952.
PubMed Abstract available

MEYER JA, Xirenayi S, Werner J, Turakulov R, et al
Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.
Br J Haematol. 2025;207:1938-1943.
PubMed Abstract available

TAMAI M, Komatsu C, Kagami K, Kasai S, et al
A characteristic gene expression profile regulated by ACIN1::NUTM1 fusion in a newly identified infant leukaemic cell line and an ACIN1::NUTM1-inducible model.
Br J Haematol. 2025;207:1842-1854.
PubMed Abstract available

HOANG T, Cheung MC, Juurlink DN, Chan KKW, et al
Outcomes following exposure to drug interactions with ibrutinib in patients with chronic lymphocytic leukaemia.
Br J Haematol. 2025;207:1893-1901.
PubMed Abstract available

SHIMONI A, Peczynski C, Labopin M, Dominietto A, et al
Graft-versus-host disease is not associated with reduced incidence of relapse following haploidentical stem cell transplantation with post-transplant cyclophosphamide for acute lymphoblastic leukaemia: A study on behalf of the Acute Leukaemia Working
Br J Haematol. 2025;207:2041-2048.
PubMed Abstract available

ROKKANEN R, Aarnivala H, Huhtaniska S, Palmu S, et al
Follow-up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol.
Br J Haematol. 2025;207:1912-1919.
PubMed Abstract available

October 2025

SHICHIJO T, Tatetsu H, Higuchi Y, Miyakawa T, et al
Prognostic impact of valemetostat in relapsed/refractory adult T-cell leukaemia-lymphoma.
Br J Haematol. 2025 Oct 23. doi: 10.1111/bjh.70219.
PubMed Abstract available

ZHANG X, Wang L, Kuang N, Yang J, et al
Immune reconstitution after CD7 CAR-T cell therapy for refractory/relapsed acute T-lymphoblastic leukaemia/lymphoblastic lymphoma (R/R T-ALL/LBL).
Br J Haematol. 2025 Oct 19. doi: 10.1111/bjh.70201.
PubMed Abstract available

POURHASSAN H, Tinajero J, Ma H, Jackson R, et al
The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia.
Br J Haematol. 2025;207:1377-1387.
PubMed Abstract available

NACHMIAS B, Haran A, Yisraeli Salman M, Stein EM, et al
Measurable residual disease-guided therapy in acute myeloid leukaemia: Practical insights.
Br J Haematol. 2025;207:1192-1212.
PubMed Abstract available

SHARMA P, Leons GK, Singh V, Naseer S, et al
Gene expression signature of IKZF1 deleted B-cell acute lymphoblastic leukaemia reveals a unique regulation of MUC4.
Br J Haematol. 2025;207:1259-1270.
PubMed Abstract available

LIANG H, He B, Chen J, Luo B, et al
Paediatric-inspired regimen reduces central nervous system relapse in adult acute lymphoblastic leukaemia.
Br J Haematol. 2025;207:1445-1453.
PubMed Abstract available

EGGER-HEIDRICH K, Sockel K, Schetelig J
Back to life: Biological parenthood of young adult acute leukaemia survivors.
Br J Haematol. 2025;207:1728-1730.
PubMed Abstract available

HERLIN MK, Kjeldsen E, Abrahamsson J, Arad-Cohen N, et al
Characteristics and prognosis of paediatric normal karyotype acute myeloid leukaemia: A NOPHO-DBH AML study.
Br J Haematol. 2025;207:1454-1463.
PubMed Abstract available

SHI H, Shu W, Tao Y, Jia X, et al
White blood cell count as a powerful prognostic marker and treatment guide in paediatric acute myeloid leukaemia with NUP98 rearrangement.
Br J Haematol. 2025;207:1464-1475.
PubMed Abstract available

YUAN M, Zhang Y, Liu B, Zhou L, et al
Treatment-free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure.
Br J Haematol. 2025;207:1408-1415.
PubMed Abstract available

LIU Y, Liu W, Mei Y, Huang Q, et al
Single-cell transcriptome profiling reveals blast cell heterogeneity and identifies novel therapeutic target IKZF2 in t(8;21) acute myeloid leukaemia.
Br J Haematol. 2025;207:1309-1322.
PubMed Abstract available

ZHONG M, Yin C, Wang Y, Zeng L, et al
HOX11 gene overexpression is associated with recurrence of acute B lymphoblastic leukaemia.
Br J Haematol. 2025;207:1301-1308.
PubMed Abstract available

HUANG N, Chang C, Wu L, He Q, et al
Characteristics and prognostic implications of TP53 mutations in Chinese patients with myelodysplastic syndromes.
Br J Haematol. 2025;207:1397-1407.
PubMed Abstract available

MUNYURANGABO G, Zhang L, Zhou Y, Zhang P, et al
Co-operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity.
Br J Haematol. 2025;207:1289-1300.
PubMed Abstract available

SKOPEK R, Ozcan SG, Chmiel P, Morgner S, et al
Synergistic potential of CDK4/6 inhibitors and ATRA in non-APL AML.
Br J Haematol. 2025;207:1279-1288.
PubMed Abstract available

DANYLESKO I, Shimoni A, Avigdor A, Kedmi M, et al
Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II study.
Br J Haematol. 2025;207:1425-1434.
PubMed Abstract available

SCHONUNG M, Rathmann S, Ramamoorthy S, Lebrecht D, et al
Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study.
Br J Haematol. 2025;207:1271-1278.
PubMed Abstract available

ANGOTZI F, Cellini A, Danesin N, Zoletto S, et al
Serum soluble interleukin-2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring.
Br J Haematol. 2025;207:1357-1365.
PubMed Abstract available

DREYZIN A, Holtzman NG, Bonifant CL
CD123-targeting immunotherapeutic approaches in acute myeloid leukaemia.
Br J Haematol. 2025;207:1178-1191.
PubMed Abstract available

JENSEN RH, Teglgaard C, Jensen JF, Baech J, et al
Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study.
Br J Haematol. 2025;207:1416-1424.
PubMed Abstract available

NIELSEN NN, Jensen JF, Ovlisen A, Zenas DR, et al
Reproductive patterns and birth rates in acute leukaemia survivors: A Danish population-based cohort study.
Br J Haematol. 2025;207:1435-1444.
PubMed Abstract available

September 2025

LI Y, Jin L, Liu W, Liu Y, et al
Clinical features, mutational landscape and their prognostic impact in Chinese paediatric patients with T-cell lymphoblastic lymphoma.
Br J Haematol. 2025 Sep 16. doi: 10.1111/bjh.70097.
PubMed Abstract available

LI X, Zhou Q, Hao X, Cao C, et al
Targeting NLRP1-CCL8 axis in the leukaemic niche suppresses AML via inhibition of PI3K-AKT signalling.
Br J Haematol. 2025;207:789-801.
PubMed Abstract available

CHENG CN, Yang YN, Yeh YH, Chen JS, et al
The impact of secondary hypogammaglobulinaemia in children with acute lymphoblastic leukaemia receiving maintenance chemotherapy.
Br J Haematol. 2025;207:892-901.
PubMed Abstract available

KOSYDAR S, Archibald WJ, Hampel PJ, Call TG, et al
The role of imaging studies in predicting time to first treatment and overall survival in high-count monoclonal B-cell lymphocytosis.
Br J Haematol. 2025;207:860-868.
PubMed Abstract available

ZU Y, Yue X, Zhan X, Liu X, et al
Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes.
Br J Haematol. 2025;207:834-841.
PubMed Abstract available

ROLLES B, Chatain N, Gorg R, Vieri M, et al
ZIP10 as a potential therapeutic target in acute myeloid leukaemia.
Br J Haematol. 2025;207:767-779.
PubMed Abstract available

August 2025

YU F, Yu X, Hu X, Jiang E, et al
Comprehensive risk stratification for adult T-cell lymphoblastic lymphoma undergoing allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2025 Aug 26. doi: 10.1111/bjh.70102.
PubMed Abstract available

TE VRUGT M, Newman H, Teachey DT, Burkhardt B, et al
T-cell lymphoblastic lymphoma in children, adolescents and young adults.
Br J Haematol. 2025 Aug 13. doi: 10.1111/bjh.70053.
PubMed Abstract available

TINAJERO J, Ngo D, Motta M, Agrawal V, et al
The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission.
Br J Haematol. 2025;207:426-431.
PubMed Abstract available

BORJA-MONTES OF, Toro-Pedroza A, Epperla N, Andritsos LA, et al
Hairy cell leukaemia and pregnancy: A systematic review and review of literature.
Br J Haematol. 2025;207:678-682.
PubMed Abstract available

NACHTKAMP K, Schulz F, Gattermann N, Germing U, et al
Clinical management of CMML-State of the art.
Br J Haematol. 2025;207:350-364.
PubMed Abstract available

SAVONA MR, Odenike O, Roboz GJ, Amin H, et al
Efficacy and safety of oral decitabine/cedazuridine in the chronic myelomonocytic leukaemia subpopulations from phase 2 and 3 studies.
Br J Haematol. 2025;207:432-444.
PubMed Abstract available

KONUMA T, Shimomura Y, Mizuno S, Yamasaki S, et al
Prognostic factors for allogeneic haematopoietic cell transplantation outcomes in primary refractory acute myeloid leukaemia (2013-2022): A retrospective study by the adult acute myeloid leukaemia working group of the Japanese Society for Transplantat
Br J Haematol. 2025;207:484-497.
PubMed Abstract available

XIAO J, Xia Y, Yin F, Shi Z, et al
Global spatiotemporal distribution characteristics and regional risk stratification model of acute myeloid leukaemia based on molecular genetics and cytogenetic features.
Br J Haematol. 2025;207:395-406.
PubMed Abstract available

July 2025

YE Y, Liu X, Dai H, Hu J, et al
Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study.
Br J Haematol. 2025;207:151-161.
PubMed Abstract available

WANG M, Guo Z, Zhao S, Liu L, et al
CD49d promotes T-cell senescence in chronic lymphocytic leukaemia.
Br J Haematol. 2025;207:80-91.
PubMed Abstract available

WILKE AC, Gokbuget N
The role of blinatumomab in adult acute B lymphoblastic leukaemia.
Br J Haematol. 2025;207:27-42.
PubMed Abstract available

LIN ME, Hsu YC, Chiu HL, Yao CY, et al
Inhibition of DOCK1 suppresses Notch signalling pathway and impairs leukaemogenesis.
Br J Haematol. 2025;207:59-68.
PubMed Abstract available

BEHRENS YL, Reinkens T, Hofmann W, Gumann A, et al
Genomic variant profiling in blast-phase paediatric chronic myeloid leukaemia: Predisposing and driving alterations.
Br J Haematol. 2025;207:141-150.
PubMed Abstract available

LUO Y, Fu Y, Kuang M, Wang J, et al
Ciclosporin A potentiates venetoclax efficacy in FLT3-ITD AML by targeting the NFATC1-AKT-mTOR-BCL-2/MCL-1 signaling axis.
Br J Haematol. 2025;207:46-58.
PubMed Abstract available

June 2025

AGRAWAL V, Arslan S, Pourhassan H, Koller P, et al
Hypomethylating agent and venetoclax are effective salvage therapies in relapsed/refractory early T-cell precursor acute lymphoblastic leukaemia.
Br J Haematol. 2025;206:1678-1682.
PubMed Abstract available

HEIBLIG M, Plesa A, Tantot J, Jamilloux Y, et al
Myeloid neoplasm inspired intensive therapy in VEXAS syndrome: A single-centre experience.
Br J Haematol. 2025;206:1683-1688.
PubMed Abstract available

HUANG YJ, Liu HC, Kuo MC, Yeh TC, et al
Frequency and prognostic value of unconventional genetic subtypes in paediatric and young adult B-cell precursor acute lymphoblastic leukaemia in Taiwan.
Br J Haematol. 2025;206:1699-1709.
PubMed Abstract available

May 2025

AOKI T, Salib M, Suleman A, Ghanem N, et al
Distinct characteristics and social determinants in adult T-cell leukaemia/lymphoma patients at a tertiary cancer centre in Canada.
Br J Haematol. 2025 May 6. doi: 10.1111/bjh.20132.
PubMed Abstract available

SCARADAVOU A
Cord blood transplants: Advancing leukaemia treatments and addressing health disparities.
Br J Haematol. 2025;206:1312-1314.
PubMed Abstract available

ZHENG Z, Wang W, Feng M, Chen X, et al
The mechanism of EZH2/H3K27me3 downregulating CXCL10 to affect CD8(+) T cell exhaustion to participate in the transformation from myelodysplastic syndrome to acute myeloid leukaemia.
Br J Haematol. 2025;206:1335-1349.
PubMed Abstract available

VICENTE-GARCES C, Fernandez G, Esperanza-Cebollada E, Richarte-Franques M, et al
RNA-sequencing: A reliable tool to unveil transcriptional landscape of paediatric B-other acute lymphoblastic leukaemia.
Br J Haematol. 2025;206:1355-1365.
PubMed Abstract available

LIU J, Zhao XS, Chang YJ, Qin YZ, et al
Monitoring the KMT2A gene post-chemotherapy independently predicts the relapse and survival risk after allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2025;206:1418-1429.
PubMed Abstract available

SUTTORP M, Sembill S, Lensker P, Hildebrand V, et al
Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real-world setting.
Br J Haematol. 2025;206:1397-1405.
PubMed Abstract available

STASIK S, Eckardt JN, Rollig C, Baldus CD, et al
The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML.
Br J Haematol. 2025;206:1373-1379.
PubMed Abstract available

April 2025

ZHAO C, Xiao MY, Zhang F, Bai L, et al
Outcomes and prognostic factors associated with relapse after haploidentical stem cell transplantation for paediatric T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2025;206:1165-1172.
PubMed Abstract available

CONNERTY P, Xie J, El-Najjar F, Trahair TN, et al
Immune-deficient MISTRG mice support expansion of leukaemia-initiating cells in xenograft models of paediatric acute myeloid leukaemia.
Br J Haematol. 2025;206:1092-1096.
PubMed Abstract available

PRATZ KW
Advancing the outcomes of AML out of antecedent MPN by targeting mutated IDH1.
Br J Haematol. 2025;206:1250-1252.
PubMed Abstract available

FRERICH C, Li P, Raess PW, Dunlap J, et al
Landscape of somatic mutations and clonal evolution in NUP98-rearranged adult acute myeloid leukaemia.
Br J Haematol. 2025;206:1097-1102.
PubMed Abstract available

DE BOTTON S, Recher C, Cortes J, Curti A, et al
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm.
Br J Haematol. 2025;206:1121-1128.
PubMed Abstract available

March 2025

PERUTELLI F, Boccellato E, Montalbano MC, Catania G, et al
Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2025;206:924-929.
PubMed Abstract available

SERAFIN A, Ruocco V, Cellini A, Angotzi F, et al
Management strategies for patients with chronic lymphocytic leukaemia harbouring complex karyotype.
Br J Haematol. 2025;206:832-841.
PubMed Abstract available

VALTIS YK, Luskin MR
Better late than never: Delayed asparaginase during induction for acute lymphoblastic leukaemia in adults.
Br J Haematol. 2025;206:1016-1017.
PubMed Abstract available

LAING A, Elmarghany A, Alghaith AA, Gouma A, et al
Paediatric bone marrow mesenchymal stem cells support acute myeloid leukaemia cell survival and enhance chemoresistance via contact-independent mechanism.
Br J Haematol. 2025;206:858-863.
PubMed Abstract available

TINAJERO J, Xu S, Ngo D, Li S, et al
Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes.
Br J Haematol. 2025;206:868-875.
PubMed Abstract available

February 2025

ZHAO J, Liu TF, Wu KF, Yang LC, et al
Clinical and molecular characteristics of paediatric mature B-cell acute lymphocytic leukaemia and non-Hodgkin lymphoma with bone marrow involvement: A joint study between the CCCG leukaemia and lymphoma groups.
Br J Haematol. 2025 Feb 17. doi: 10.1111/bjh.20011.
PubMed Abstract available

CHEN Z, Ren A, Li Y, Shu J, et al
mRNA-laden lipid nanoparticle-enabled humanized CD19 CAR-T-cell engineering for the eradication of leukaemic cells.
Br J Haematol. 2025;206:628-643.
PubMed Abstract available

LIN CC, Hsu CL, Yao CY, Wang YH, et al
HOPX as a tumour-suppressive protein in T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2025;206:505-516.
PubMed Abstract available

GANZEL C, Frisch A, Wolach O, Moshe Y, et al
CPX-351 +/- gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable-intermediate risk, FLT3-ITD negative, AML: A pilot study.
Br J Haematol. 2025;206:551-555.
PubMed Abstract available

GURNARI C, Visconte V
Dissecting the genomic traits and clinical course of secondary myelodysplastic syndrome following aplastic anaemia: A milestone.
Br J Haematol. 2025;206:790-791.
PubMed Abstract available

ESTELLER M
Targeting RNA modifications in leukaemia: Epitranscriptomic drugs are the new kids on the block.
Br J Haematol. 2025;206:785-787.
PubMed Abstract available

CHEN X, Gong RZ, Mo LY, Cheng YT, et al
Hydroxy-wybutosine tRNA modifications as indicators of disease progression and therapeutic targets in leukaemia.
Br J Haematol. 2025;206:517-530.
PubMed Abstract available

January 2025

SWEET K, Cluzeau T
Clinical perspectives on post-induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2025;206:61-68.
PubMed Abstract available

COSTA A, Scalzulli E, Breccia M
Chronic eosinophilic leukaemia-Not otherwise specified: Clinical features, genomic insight and therapeutic strategies.
Br J Haematol. 2025;206:44-60.
PubMed Abstract available

HA TQ, Andresen V, Erikstein BS, Popa M, et al
Preclinical activity of resazurin in acute myeloid leukaemia.
Br J Haematol. 2025;206:109-119.
PubMed Abstract available

JIANG L, Cheng J, Sun J, Zhang Y, et al
Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission.
Br J Haematol. 2025;206:250-262.
PubMed Abstract available

VEDI A, Leiter SM, Memon IL, Mahendrayogam A, et al
Real-world experience of paediatric acute promyelocytic leukaemia in the United Kingdom and Ireland.
Br J Haematol. 2025;206:204-208.
PubMed Abstract available

DAVIDS MS, Lin KH, Mohamed AI, Munir T, et al
Measurable residual disease-driven treatment in first-line chronic lymphocytic leukaemia.
Br J Haematol. 2025;206:33-43.
PubMed Abstract available

TRKA J, Fronkova E
Minimal residual disease detection for acute lymphoblastic leukaemia in peripheral blood-Are we there yet?
Br J Haematol. 2025;206:397-398.
PubMed Abstract available

HUANG Q, Jiang X, Wang B, Wu Z, et al
Gallic acid enhances GVL effects of T cells without exacerbating GVHD after haematopoietic stem cell transplantation.
Br J Haematol. 2025;206:120-132.
PubMed Abstract available

THERON A, Alonso-Saladrigues A, Dapena JL, Lopez-Duarte M, et al
Secondary haematological dysplasia after CAR-T-cell therapy for acute lymphoblastic leukaemia in children.
Br J Haematol. 2025;206:186-194.
PubMed Abstract available

COUSSON S, Calvo C, Goldwirt L, Simonin M, et al
Monocentric experience of venetoclax-based regimen in paediatric refractory and relapsed AML/MDS.
Br J Haematol. 2025;206:209-214.
PubMed Abstract available

December 2024

FROST EL, Chonat S, Williams KM, Aumann W, et al
Fatal thrombotic microangiopathy during induction for acute myeloid leukemia: A case report and review of vascular complications in germline GATA2 haploinsufficiency.
Br J Haematol. 2024 Dec 8. doi: 10.1111/bjh.19935.
PubMed

HUGUET F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, et al
Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study.
Br J Haematol. 2024;205:2295-2304.
PubMed Abstract available

MORIGUCHI M, Nakamae H, Nishimoto M, Sugita J, et al
Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia.
Br J Haematol. 2024;205:2376-2386.
PubMed Abstract available

KONDO T
A new face in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:2131-2133.
PubMed Abstract available

PULA AE, Robak T
The discovery of the RCC1::IRF4 Fusion in CLL patients with t(1;6)(p35.3;p25.2) chromosomal translocation.
Br J Haematol. 2024;205:2125-2127.
PubMed Abstract available

BOUSSI L, Biswas J, Abdel-Wahab O, Stein E, et al
Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies.
Br J Haematol. 2024;205:2153-2162.
PubMed Abstract available

JAYNE S, Lopez C, Put N, Nagel I, et al
The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion.
Br J Haematol. 2024;205:2321-2326.
PubMed Abstract available

TERUEL-MONTOYA R, Rivera J, Lozano ML
The importance of genetic variant cleaners: From patient to wet lab and back to clinical practice.
Br J Haematol. 2024;205:2122-2124.
PubMed Abstract available

KAMIYA LJ, Barozzi S, Isidori F, Ganiewich D, et al
Two novel families with RUNX1 variants indicate glycine 168 as a new mutational hotspot: Implications for FPD/AML diagnosis.
Br J Haematol. 2024;205:2315-2320.
PubMed Abstract available

LIU W, Wang C, Ouyang W, Hao J, et al
Efficacy and safety of olverembatinib in adult BCR::ABL1-positive ALL with T315I mutation or relapsed/refractory disease.
Br J Haematol. 2024;205:2228-2233.
PubMed Abstract available

ASHOURI K, Hom B, Ginosyan AA, Rahimi Y, et al
Philadelphia-like B-cell acute lymphoblastic leukaemia: Disease features and outcomes in the era of immunotherapy.
Br J Haematol. 2024;205:2234-2247.
PubMed Abstract available

November 2024

LV M, Yan CH, Ma R, He Y, et al
Mega-dose decitabine conditioning and prophylactic donor lymphocyte infusion for patients with relapsed/refractory AML with active disease at the time of allogeneic haematopoietic cell transplantation: A multicenter prospective phase II study.
Br J Haematol. 2024;205:1910-1920.
PubMed Abstract available

BOULIGNY IM, DiNardo CD
Oral decitabine-cedazuridine in acute myeloid leukaemia.
Br J Haematol. 2024;205:1674-1676.
PubMed Abstract available

GEISSLER K, Koristek Z, Del Castillo TB, Novak J, et al
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study.
Br J Haematol. 2024;205:1734-1745.
PubMed Abstract available

PHILIP C, Selvarajan S, Nayak L, Jain H, et al
Impact of the COVID-19 pandemic on treatment of patients with acute myeloid leukaemia in India.
Br J Haematol. 2024;205:2058-2062.
PubMed Abstract available

YANADA M
Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia.
Br J Haematol. 2024;205:1672-1673.
PubMed Abstract available

MAILLET F, Galimard JE, Borie R, Lainey E, et al
Haematological features of telomere biology disorders diagnosed in adulthood: A French nationwide study of 127 patients.
Br J Haematol. 2024;205:1835-1847.
PubMed Abstract available

ARIFFIN H
Incorrigible inflammation.
Br J Haematol. 2024;205:1679-1680.
PubMed Abstract available

CICCONI L, Bisegna M, Gurnari C, Fanciullo D, et al
Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications.
Br J Haematol. 2024;205:1727-1733.
PubMed Abstract available

SPECTOR LG, de Smith AJ
Backtracking childhood leukaemia to birth: A battle of addition.
Br J Haematol. 2024;205:1670-1671.
PubMed Abstract available

YANG YT, Yao CY, Kao CJ, Chiu PJ, et al
Clinical relevance of NFYA splice variants in patients with acute myeloid leukaemia undergoing intensive chemotherapy.
Br J Haematol. 2024;205:1751-1764.
PubMed Abstract available

XU N, Dao FT, Shi ZY, Sun K, et al
WT1 together with RUNX1::RUNX1T1 targets DUSP6 to dampen ERK activity in acute myeloid leukaemia.
Br J Haematol. 2024;205:1848-1859.
PubMed Abstract available

ZHU Q, Nambiar R, Schultz E, Gao X, et al
Genome-wide study identifies novel genes associated with bone toxicities in children with acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:1889-1898.
PubMed Abstract available

BARDINI M, Fazio G, Abascal LC, Meyer C, et al
Prenatal origin of NUTM1 gene rearrangement in infant B-cell precursor acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:1883-1888.
PubMed Abstract available

WEINBERGEROVA B, Mayer J, Kabut T, Sperr WR, et al
Fungal infection frequency in newly diagnosed acute myeloid leukaemia patients treated with venetoclax plus azacitidine with or without antifungal prophylaxis.
Br J Haematol. 2024;205:1746-1750.
PubMed Abstract available

October 2024

YOSHIMITSU M, Tanaka T, Nakano N, Kato K, et al
Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma.
Br J Haematol. 2024 Oct 19. doi: 10.1111/bjh.19835.
PubMed Abstract available

NAKAMURA M, Chonabayashi K, Narita M, Matsumura Y, et al
Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs.
Br J Haematol. 2024;205:1430-1443.
PubMed Abstract available

GHOSH N, Manzoor BS, Fakhri B, Emechebe N, et al
Real-world comparative effectiveness of venetoclax-obinutuzumab versus Bruton tyrosine kinase inhibitors for frontline chronic lymphocytic leukaemia.
Br J Haematol. 2024;205:1395-1403.
PubMed Abstract available

GAO MY, Georgiou A, Lin VS, Jahja M, et al
Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications.
Br J Haematol. 2024;205:1389-1394.
PubMed Abstract available

MEHTA P, Campbell V, Maddox J, Floisand Y, et al
CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK.
Br J Haematol. 2024;205:1326-1336.
PubMed Abstract available

ANASTASOPOULOU S, Swann G, Andres-Jensen L, Attarbaschi A, et al
Severe steroid-related neuropsychiatric symptoms during paediatric acute lymphoblastic leukaemia therapy-An observational Ponte di Legno Toxicity Working Group Study.
Br J Haematol. 2024;205:1450-1459.
PubMed Abstract available

September 2024

NARESH KN
Understanding splenic B-cell lymphoma/leukaemia with prominent nucleoli: Diagnosis, underpinnings for disease classification and future directions.
Br J Haematol. 2024 Sep 10. doi: 10.1111/bjh.19754.
PubMed Abstract available

HEI Z, Yang S, Ouyang G, Hanna J, et al
Targeting the redox vulnerability of acute myeloid leukaemia cells with a combination of auranofin and vitamin C.
Br J Haematol. 2024;205:1017-1030.
PubMed Abstract available

LEBLANC FR, Breese EH, Burns KC, Chang EK, et al
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.
Br J Haematol. 2024;205:1055-1066.
PubMed Abstract available

HUANG C, Jia Y, Yang J, Cai Y, et al
Azacitidine combined with interferon-alpha for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.
Br J Haematol. 2024;205:1067-1076.
PubMed Abstract available

GOVER-PROAKTOR A, Leshem-Lev D, Winograd-Katz S, Partouche S, et al
Dasatinib induces endothelial dysfunction leading to impaired recovery from ischaemia.
Br J Haematol. 2024;205:1011-1016.
PubMed Abstract available

KUGLER E, Cohen I, Amitai I, Ram R, et al
Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Br J Haematol. 2024;205:932-941.
PubMed Abstract available

KUHN MWM, Ganser A
The Menin story in acute myeloid leukaemia-The road to success.
Br J Haematol. 2024;205:812-814.
PubMed Abstract available

ZHAO S, Wang J, Lou Y, Huang X, et al
Clinical characteristics of acute myeloid leukaemia patients with a large number of azurophilic granules: A single-centre retrospective study.
Br J Haematol. 2024;205:924-931.
PubMed Abstract available

ROBERTSON HF, Milojkovic D, Butt N, Byrne J, et al
Expectations and outcomes of varying treatment strategies for CML presenting during pregnancy.
Br J Haematol. 2024;205:947-955.
PubMed Abstract available

MARCHAND T, Pastoret C, Damaj G, Lebouvier A, et al
Efficacy of ruxolitinib in the treatment of relapsed/refractory large granular lymphocytic leukaemia.
Br J Haematol. 2024;205:915-923.
PubMed Abstract available

August 2024

GLANZMANN J, Kalberer C, Bonadies N, Colucci G, et al
Plasma cells with Auer-rod-like inclusions in a patient with MGUS and acute myeloid leukaemia with NPM1 mutation.
Br J Haematol. 2024;205:401-402.
PubMed

YANG F, Ren Q, Zu Y, Gui R, et al
Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemia.
Br J Haematol. 2024;205:645-652.
PubMed Abstract available

TRINQUAND A, Betts DR, Rooney S, Storey L, et al
MRD-risk stratification mitigates TLX3 prognostic impact in paediatric T-cell acute lymphoblastic leukaemia: A national cohort analysis.
Br J Haematol. 2024;205:729-732.
PubMed

CHEN C, Li J, Chen Y, Gao Q, et al
The correlation of asparaginase enzyme activity levels after PEG-asparaginase administration with clinical characteristics and adverse effects in Chinese paediatric patients with acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:624-633.
PubMed Abstract available

ZHU W, Ding Y, Huang W, Guo N, et al
Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI-503 against MLL::AF9-driven acute myeloid leukaemia.
Br J Haematol. 2024;205:568-579.
PubMed Abstract available

GRADY E, Biswas S, Dias T, McCarthy P, et al
A novel TCF3::PIK3R1 fusion linked to decreased PI3K-AKT signalling activity in paediatric B-acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:738-741.
PubMed

OTHMAN T, Koller P, Pourhassan H, Agrawal V, et al
Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:711-715.
PubMed

WANG S, Liu Y, Zhao X, Wang X, et al
RUNX1::ETO and CBFbeta::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core-binding factor-acute myeloid leukaemia.
Br J Haematol. 2024;205:552-567.
PubMed Abstract available

TANG FF, Duan WB, Liu XH, Lu SY, et al
A complete oral regimen for induction therapy of patients with high-risk APL: An oral etoposide instead of intravenous infusion for cytoreductive chemotherapy.
Br J Haematol. 2024;205:510-516.
PubMed Abstract available

NGUYEN-KHAC F, Baron M, Guieze R, Feugier P, et al
Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
Br J Haematol. 2024;205:495-502.
PubMed Abstract available

XU X, Huang Z, Ding C, Deng S, et al
STAT5 phosphorylation plus minimal residual disease defines a novel risk classification in adult B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:517-528.
PubMed Abstract available

BOTTEN GA, Zhang Y, Fuda F, Koduru P, et al
T/myeloid mixed phenotype acute leukaemia harbouring TLX3::BCL11B with TLX3 activation.
Br J Haematol. 2024;205:607-612.
PubMed Abstract available

July 2024

ALLEN B, Savoy L, Ryabinin P, Bottomly D, et al
Upregulation of HOXA3 by isoform-specific Wilms tumour 1 drives chemotherapy resistance in acute myeloid leukaemia.
Br J Haematol. 2024;205:207-219.
PubMed Abstract available

RONNACKER J, Urbahn MA, Reicherts C, Kolloch L, et al
Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia.
Br J Haematol. 2024;205:280-290.
PubMed Abstract available

JIMENEZ-VICENTE C, Charry P, Castano-Diez S, Guijarro F, et al
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group.
Br J Haematol. 2024;205:256-267.
PubMed Abstract available

PICHLER H, Sedlacek P, Meisel R, Beier R, et al
Haematopoietic stem cell transplantation after reduced intensity conditioning in children and adolescents with chronic myeloid leukaemia: A prospective multicentre trial of the I-BFM Study Group.
Br J Haematol. 2024;205:268-279.
PubMed Abstract available

TAURINO G, Dander E, Chiu M, Pozzi G, et al
Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP-ALL cell survival and a potential therapeutic target.
Br J Haematol. 2024;205:175-188.
PubMed Abstract available

WANG HY, Louis HMS, Costello CL, Murray SS, et al
A CD10-negative adult B-lymphoblastic leukaemia with amplification of KMT2A without rearrangement: A case report and review of the English literature.
Br J Haematol. 2024;205:364-367.
PubMed

DOURTHE ME, Yakouben K, David A, Thouvenin S, et al
Success of donor-derived CAR-T cells after failure of autologous CD19 CAR-T cells (tisagenlecleucel) in B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2024;205:373-377.
PubMed

JEN WY, Kantarjian H, Kadia TM, DiNardo CD, et al
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
Br J Haematol. 2024;205:30-47.
PubMed Abstract available

SERAFIN A, Cellini A, Cavarretta CA, Ruocco V, et al
Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens.
Br J Haematol. 2024;205:189-193.
PubMed Abstract available

ZHANG X, Zhong Y, Liu L, Suo S, et al
MN1::ETV6-positive de novo T-cell acute lymphoblastic leukaemia is sensitive to venetoclax: A case report.
Br J Haematol. 2024;205:352-355.
PubMed

IYENGAR L, Fong CY, Prakash S, Chong AH, et al
Cutaneous involvement in chronic lymphocytic leukaemia.
Br J Haematol. 2024;205:11.
PubMed

POURHASSAN H, Zhang J, Tinajero J, Pullarkat V, et al
Therapy-related acute lymphoblastic leukaemia in women with antecedent breast cancer.
Br J Haematol. 2024;205:158-165.
PubMed Abstract available

June 2024

XU J, Peng J, Sun S, Wang D, et al
Preclinical testing of CT1113, a novel USP28 inhibitor, for the treatment of T-cell acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:2301-2318.
PubMed Abstract available

DELGADO J
InsT-ALLing CD7 chimeric antigen receptors before transplantation.
Br J Haematol. 2024;204:2155-2156.
PubMed Abstract available

ENJETI AK, Fogler WE, Smith TAG, Lincz LF, et al
Combining 5-azacitidine with the E-selectin antagonist uproleselan is an effective strategy to augment responses in myelodysplasia and acute myeloid leukaemia.
Br J Haematol. 2024;204:2264-2274.
PubMed Abstract available

ORTIZ ROJAS CA, Pereira-Martins DA, Bellido More CC, Sternadt D, et al
A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction.
Br J Haematol. 2024;204:2287-2300.
PubMed Abstract available

LIU H, Wu K, Hu W, Chen X, et al
Immunophenotypic clustering in paediatric acute myeloid leukaemia.
Br J Haematol. 2024;204:2275-2286.
PubMed Abstract available

MAO S, Lin Y, Qin X, Miao Y, et al
Droplet digital PCR: An effective method for monitoring and prognostic evaluation of minimal residual disease in JMML.
Br J Haematol. 2024;204:2332-2341.
PubMed Abstract available

JEN WY, Sasaki K, Loghavi S, Wang SA, et al
Characteristics and outcomes of acute myeloid leukaemia patients with baseline CD7 expression.
Br J Haematol. 2024;204:2259-2263.
PubMed Abstract available

KINSELLA FAM, Maroto MAL, Loke J, Craddock C, et al
Strategies to reduce relapse risk in patients undergoing allogeneic stem cell transplantation for acute myeloid leukaemia.
Br J Haematol. 2024;204:2173-2183.
PubMed Abstract available

ROLLIG C, Schliemann C, Ruhnke L, Fransecky L, et al
Gemtuzumab ozogamicin plus midostaurin in combination with standard '7 + 3' induction therapy in newly diagnosed AML: Results from the SAL-MODULE phase I study.
Br J Haematol. 2024;204:2254-2258.
PubMed Abstract available

ONIDA F, Gras L, Ge J, Koster L, et al
Mismatched related donor allogeneic haematopoietic cell transplantation compared to other donor types for Ph+ chronic myeloid leukaemia: A retrospective analysis from the Chronic Malignancies Working Party of the EBMT.
Br J Haematol. 2024;204:2365-2377.
PubMed Abstract available

HARROP S, Nguyen PC, Robinson S, Nguyen T, et al
Immunophenotypic characterisation of acute myeloid leukaemia with UBTF tandem duplications.
Br J Haematol. 2024;204:2492-2495.
PubMed

BARNBROCK A, Moricke A, Barbaric D, Jones N, et al
Pneumocystis jirovecii pneumonia in paediatric acute lymphoblastic leukaemia: A report from the multi-international clinical trial AIEOP-BFM ALL 2009.
Br J Haematol. 2024;204:2319-2323.
PubMed Abstract available

DONG Q, Wang Y, Xiu Y, Wu X, et al
Unveiling myeloid transformation: T-LGLL with eosinophilia masking myeloid-associated STAT5B mutation culminating in AML.
Br J Haematol. 2024;204:2487-2491.
PubMed

BAUCH T, Hempel G
Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:2324-2331.
PubMed Abstract available

May 2024

RUPAKUMAR T, Sankar A, Vijayasekharan K, Varikkattu Rajendran P, et al
Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)-induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India.
Br J Haematol. 2024 May 26. doi: 10.1111/bjh.19559.
PubMed Abstract available

BALDUZZI A
The CAR T-cell race: The rules of the game.
Br J Haematol. 2024;204:1579-1581.
PubMed Abstract available

ZHANG X, Tao C, Long F
Haematoidin in chronic myelomonocytic leukaemia during irregular treatment with hydroxycarbamide.
Br J Haematol. 2024;204:1569-1570.
PubMed

MISHRA AK, Burridge S, Espuelas MO, O'Reilly M, et al
Practice guideline: Preparation for CAR T-cell therapy in children and young adults with B-acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1687-1696.
PubMed Abstract available

KRIEGER E, Qayyum R, Toor A
Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia.
Br J Haematol. 2024;204:1935-1943.
PubMed Abstract available

LEBECQUE B, Besombes J, Dannus LT, De Antonio M, et al
Faster clinical decisions in B-cell acute lymphoblastic leukaemia: A single flow cytometric 12-colour tube improves diagnosis and minimal residual disease follow-up.
Br J Haematol. 2024;204:1872-1881.
PubMed Abstract available

JO T, Ueda T, Akahoshi Y, Kondo T, et al
First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1913-1919.
PubMed Abstract available

BOUKOUACI W, Rivera-Franco MM, Volt F, Lajnef M, et al
HLA peptide-binding pocket diversity modulates immunological complications after cord blood transplant in acute leukaemia.
Br J Haematol. 2024;204:1920-1934.
PubMed Abstract available

BRILLEMBOURG H, Martinez-Cibrian N, Bachiller M, Alserawan L, et al
The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies.
Br J Haematol. 2024;204:1649-1659.
PubMed Abstract available

LOH Z, Ashby M, Van Veldhuizen E, Li W, et al
Arsenic-induced neurotoxicity in patients with acute promyelocytic leukaemia.
Br J Haematol. 2024;204:1732-1739.
PubMed Abstract available

April 2024

HUO W, Gao L, Song K, Huang J, et al
Allogeneic haematopoietic stem cell transplantation for adult T-lymphoblastic lymphoma: A real-world multicentre analysis in China.
Br J Haematol. 2024 Apr 25. doi: 10.1111/bjh.19481.
PubMed Abstract available

CAO XY, Zhang JP, Lu Y, Zhao YL, et al
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen r
Br J Haematol. 2024 Apr 13. doi: 10.1111/bjh.19445.
PubMed Abstract available

LIU HC, Huang YJ, Jaing TH, Wu KH, et al
Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1(plus) and Day 15 MRD positivity.
Br J Haematol. 2024;204:1344-1353.
PubMed Abstract available

BOMMANNAN K, Arumugam JR, Radhakrishnan V, Sundersingh S, et al
Relevance of CD20 antigen expression among paediatric patients with B-lineage acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1367-1374.
PubMed Abstract available

CHEN X, Li J, Yu L, Hu W, et al
High-dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study.
Br J Haematol. 2024;204:1354-1366.
PubMed Abstract available

MOSQUERA ORGUEIRA A, Perez Encinas MM, Diaz Varela N, Wang YH, et al
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification.
Br J Haematol. 2024;204:1529-1535.
PubMed Abstract available

STENTOFT J
The Mozart effect in chronic myeloid leukaemia.
Br J Haematol. 2024;204:1139-1140.
PubMed Abstract available

PATEL SA
The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia.
Br J Haematol. 2024;204:1137-1138.
PubMed Abstract available

ZHANG T, Zhang Y, Zhou M, Zhang Z, et al
Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2024;204:1402-1413.
PubMed Abstract available

ALCAZER V, Morisset S, Rea D, Legros L, et al
Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients.
Br J Haematol. 2024;204:1536-1539.
PubMed

JOHNSON IM, Karrar O, Rana M, Iftikhar M, et al
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Br J Haematol. 2024;204:1232-1237.
PubMed Abstract available

NACHMIAS B, Aumann S, Haran A, Schimmer AD, et al
Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights.
Br J Haematol. 2024;204:1146-1158.
PubMed Abstract available

ZUCENKA A, Griskevicius L
Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia.
Br J Haematol. 2024;204:1227-1231.
PubMed Abstract available

SUWANNAYING K, Ong AA, Dhaduk R, Pei D, et al
Quantitative computed tomography analysis of body composition changes in paediatric patients with acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:1335-1343.
PubMed Abstract available

FIEDLER W
Therapy with hypomethlyating agents/venetoclax in patients with newly diagnosed acute myeloid leukaemia requiring admission to the intensive care unit: Possible reduction in side effects with preserved efficacy.
Br J Haematol. 2024;204:1135-1136.
PubMed Abstract available

LIANG P, Xie Y, Liu Z, Wang D, et al
Venetoclax and hypomethylating agents in critically ill patients with newly diagnosed acute myeloid leukaemia.
Br J Haematol. 2024;204:1219-1226.
PubMed Abstract available

ROY MOULIK N, Keerthivasagam S, Pandey A, Agiwale J, et al
Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
Br J Haematol. 2024;204:1249-1261.
PubMed Abstract available

MADERO-MARROQUIN R, DuVall AS, Saygin C, Wang P, et al
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
Br J Haematol. 2024;204:1238-1242.
PubMed Abstract available

LIGIA S, Passucci M, Assanto GM, D'Elia GM, et al
Early clearance of hairy cell leukaemia in the bone marrow after first-line treatment with cladribine predicts a favourable outcome.
Br J Haematol. 2024;204:1288-1292.
PubMed Abstract available

March 2024

LARIBI K, Poulain S, Willems L, Merabet F, et al
Long-term results of Waldenstrom macroglobulinaemia treatment by bendamustine and rituximab: A study on behalf of the French Innovative Leukemia Organization (FILO).
Br J Haematol. 2024 Mar 19. doi: 10.1111/bjh.19409.
PubMed Abstract available

NG HL, Robinson ME, May PC, Innes AJ, et al
Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells.
Br J Haematol. 2024;204:945-958.
PubMed Abstract available

SUN H, Zhu Y, Li J, Zhao L, et al
CSF3R P733T is a deleterious germline variant in acute leukaemia showing gain-of-function-like T618I mutation.
Br J Haematol. 2024;204:e31-e33.
PubMed

SHIMONY S, Chen EC
Tri-ing to decipher trisomy AML.
Br J Haematol. 2024;204:751-752.
PubMed Abstract available

TAN JY, Yeo YH, Tan MC, Chavez JC, et al
Mortality trends of chronic lymphocytic leukaemia in the United States with the emergence of targeted therapy.
Br J Haematol. 2024;204:1114-1117.
PubMed

ZHAO HG
Should oligomonocytic CMML be classified as an independent disease entity?
Br J Haematol. 2024;204:749-750.
PubMed Abstract available

LAM SSY, Tsui SP, Fung CY, Saw NY, et al
Distinct karyotypic and mutational landscape in trisomy AML.
Br J Haematol. 2024;204:939-944.
PubMed Abstract available

COPLAND M, Ariti C, Thomas IF, Upton L, et al
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
Br J Haematol. 2024;204:871-876.
PubMed Abstract available

CASTANO-DIEZ S, Pomares H, Esteban D, Guijarro F, et al
Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic.
Br J Haematol. 2024;204:892-897.
PubMed Abstract available

LU Q, Qu W, Wen Y, Ke P, et al
Single-cell RNA-seq reveals the links between the metabolic heterogeneity and cell identity in NBM and AML.
Br J Haematol. 2024;204:1100-1104.
PubMed

RAVANDI F, Dohner H, Wei AH, Montesinos P, et al
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Br J Haematol. 2024;204:877-886.
PubMed Abstract available

MONTALBAN-BRAVO G, Jabbour E, Borthakur G, Kadia T, et al
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol. 2024;204:898-909.
PubMed Abstract available

CHEN N, Pan J, Zhou Y, Mao L, et al
Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia.
Br J Haematol. 2024;204:861-870.
PubMed Abstract available

February 2024

COSTA A, Breccia M
How to improve treatment-free remission eligibility in chronic myeloid leukaemia?
Br J Haematol. 2024;204:434-448.
PubMed Abstract available

PARDANANI A, Reichard K, Tefferi A
Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
Br J Haematol. 2024;204:402-414.
PubMed Abstract available

FUJI S, Yuda S, Tada Y, Kano M, et al
A treatment strategy to mitigate the adverse effect of pretransplant mogamulizumab on post-transplant clinical outcome in patients with aggressive ATL.
Br J Haematol. 2024;204:e25-e27.
PubMed

WANG Z, Fan Z, Wu Z, Xuan L, et al
PASS-ALL study of paediatric-inspired versus adult chemotherapy regimens on survival of high-risk Philadelphia-negative B-cell acute lymphoblastic leukaemia with allogeneic haematopoietic stem cell transplantation.
Br J Haematol. 2024;204:628-637.
PubMed Abstract available

KUMAR J, Ewalt MD, Zhang Y, Yao J, et al
Novel identification of t(14;18)(q32;q21)/IGH::MALT1 in chronic lymphocytic leukaemia.
Br J Haematol. 2024;204:561-565.
PubMed Abstract available

NYQUIST OE, Dalgaard J, Spetalen S, Torkildsen S, et al
Pathogenic DDX41 variants, possible response predictors to low-dose melphalan in hypo- and normocellular MDS and AML.
Br J Haematol. 2024;204:724-729.
PubMed

NARDOZZA AM, Guarnera L, Travaglini S, Ottone T, et al
Characterization of a novel IDH2-R159H mutation in acute myeloid leukaemia: Effects on cell metabolism and differentiation.
Br J Haematol. 2024;204:719-723.
PubMed

RAMAMOORTHY S, Lebrecht D, Schanze D, Schanze I, et al
Biallelic inactivation of the NF1 tumour suppressor gene in juvenile myelomonocytic leukaemia: Genetic evidence of driver function and implications for diagnostic workup.
Br J Haematol. 2024;204:595-605.
PubMed Abstract available

MARK C, Meshinchi S, Joyce B, Gibson B, et al
Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias.
Br J Haematol. 2024;204:576-584.
PubMed Abstract available

SHEN Y, Freeman JA, Kerridge I, Downe P, et al
Repeated COVID-19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL.
Br J Haematol. 2024;204:487-491.
PubMed Abstract available

BAI L, Zhang ZX, Hu GH, Cheng YF, et al
Long-term follow-up of haploidentical haematopoietic stem cell transplantation in paediatric patients with high-risk acute myeloid leukaemia: Report from a single centre.
Br J Haematol. 2024;204:585-594.
PubMed Abstract available

January 2024

MIYASHITA N, Onozawa M, Matsukawa T, Mori A, et al
Novel stratification for newly diagnosed acute myeloid leukaemia treated with venetoclax-based therapy in the real world: Hokkaido Leukemia Net Study.
Br J Haematol. 2024 Jan 18. doi: 10.1111/bjh.19292.
PubMed

NAVRKALOVA V, Plevova K, Radova L, Porc J, et al
Integrative NGS testing reveals clonal dynamics of adverse genomic defects contributing to a natural progression in treatment-naive CLL patients.
Br J Haematol. 2024;204:240-249.
PubMed Abstract available

HASSELBALCH HC, Skov V, Kjaer L, Larsen MK, et al
Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
Br J Haematol. 2024;204:16-18.
PubMed Abstract available

GJERTSEN BT
How to discover the exceptional venetoclax responders in AML/MDS?
Br J Haematol. 2024;204:14-15.
PubMed

GESTRICH CK, De Lancy SJ, Kresak A, Meyerson H, et al
IGJ and SPATS2L immunohistochemistry sensitively and specifically identify BCR::ABL1+ and BCR::ABL1-like B-acute lymphoblastic leukaemia.
Br J Haematol. 2024;204:229-239.
PubMed Abstract available

BARON F, Nagler A, Galimard JE, Sanz J, et al
Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study.
Br J Haematol. 2024;204:250-259.
PubMed Abstract available

DE CASTRO FA, Mehdipour P, Chakravarthy A, Ettayebi I, et al
Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia.
Br J Haematol. 2024;204:206-220.
PubMed Abstract available

NANAA A, He R, Foran JM, Badar T, et al
Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients.
Br J Haematol. 2024;204:171-176.
PubMed Abstract available

MURPHY EL
HTLV-1 and blood donation.
Br J Haematol. 2024;204:29-30.
PubMed Abstract available

December 2023

HOKLAND P, Fernandez II, Freeman SD, Gjertsen BT, et al
AML in the elderly-A global view.
Br J Haematol. 2023;203:760-773.
PubMed

WU JF, Abid H, Szabo A, Abid MB, et al
Impact of age on efficacy and safety of chimeric antigen receptor-T in B-cell acute lymphoblastic leukaemia-A systematic review and meta-analysis.
Br J Haematol. 2023;203:e117-e120.
PubMed

HERRITY E, Pereira MP, Kim DDH
Acute myeloid leukaemia relapse after allogeneic haematopoietic stem cell transplantation: Mechanistic diversity and therapeutic directions.
Br J Haematol. 2023;203:722-735.
PubMed Abstract available

MAHDI D, O'Nions J, Raj K, Baker R, et al
Managing molecular relapse of acute myeloid leukaemia in early pregnancy: Is a watch and wait approach reasonable?
Br J Haematol. 2023;203:e114-e116.
PubMed

QI P, Wang L, Li H, Wu Y, et al
Venetoclax as a cytoreduction therapy for acute promyelocytic leukaemia: A single-centre experience.
Br J Haematol. 2023;203:892-895.
PubMed

PERUSINI MA, Novitzky-Basso I, Atenafu EG, Forrest D, et al
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment-free remission after failing the first attempt with imatinib: Treatment-free Remission Accomplished by Dasatinib (TRAD) study.
Br J Haematol. 2023;203:781-791.
PubMed Abstract available

CHIRIAC R, Humbert C, Mejri A, Debliquis A, et al
Charcot-Leyden crystals in acute myeloid leukaemia associated with basophilia.
Br J Haematol. 2023;203:699-700.
PubMed

November 2023

NG JY, Joshi M, Choi P
Frequency and outcomes of obinutuzumab-induced thrombocytopenia.
Br J Haematol. 2023;203:668-672.
PubMed Abstract available

BORLENGHI E, Roccaro AM, Cattaneo C
Rethinking the definition of 'less intensive' for venetoclax-combining regimens in acute myeloid leukaemia patients.
Br J Haematol. 2023;203:504-506.
PubMed Abstract available

REYNOLDS G, Urbancic KF, Fong CY, Trubiano JA, et al
Invasive fungal infection following venetoclax and posaconazole co-administration.
Br J Haematol. 2023;203:593-598.
PubMed Abstract available

OCADLIKOVA D, Lussana F, Fracchiolla N, Bonifacio M, et al
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
Br J Haematol. 2023;203:637-650.
PubMed Abstract available

BOOTH E, Backx M, Joshi A, Nizami H, et al
Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
Br J Haematol. 2023;203:499-500.
PubMed

DONNETTE M, Hamimed M, Ciccolini J, Sicard G, et al
Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients.
Br J Haematol. 2023;203:625-636.
PubMed Abstract available

MONTALBAN-BRAVO G, Kanagal-Shamanna R, Li Z, Hammond D, et al
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemia.
Br J Haematol. 2023;203:581-592.
PubMed Abstract available

APOLITO V, Arrigo G, Vasseur L, Olivi M, et al
Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.
Br J Haematol. 2023;203:e98-e101.
PubMed

HILLS RK
Acute myeloid leukaemia in Afghanistan: Understanding an unfamiliar landscape.
Br J Haematol. 2023;203:353-354.
PubMed Abstract available

NOOR S, Haidary AM, Yosufzai AW, Niazai M, et al
Demographic and clinical characteristics of acute myeloid leukaemia diagnosed and treated at the tertiary level in Afghanistan.
Br J Haematol. 2023;203:404-410.
PubMed Abstract available

MOIA R, Terzi di Bergamo L, Talotta D, Bomben R, et al
XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling.
Br J Haematol. 2023;203:416-425.
PubMed Abstract available

October 2023

MARTINEZ-CIBRIAN N, Ortiz-Maldonado V, Espanol-Rego M, Blazquez A, et al
The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Br J Haematol. 2023 Oct 31. doi: 10.1111/bjh.19170.
PubMed Abstract available

PAN X, Chang Y, Ruan G, Wei F, et al
Prognostic impact of FLT3-ITD mutation on NPM1(+) acute myeloid leukaemia patients and related molecular mechanisms.
Br J Haematol. 2023;203:212-223.
PubMed Abstract available

MAHDI D, Spiers J, Rampotas A, Polverelli N, et al
Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
Br J Haematol. 2023;203:169-181.
PubMed Abstract available

SEVERIN F, Mouawad N, Ruggeri E, Visentin A, et al
Focal adhesion kinase activation by calcium-dependent calpain is involved in chronic lymphocytic leukaemia cell aggressiveness.
Br J Haematol. 2023;203:224-236.
PubMed Abstract available

TRAVAGLINI S, Gurnari C, Antonelli S, Marchesi F, et al
Functional characterization and response to FLT3 inhibitors in acute myeloid leukaemia with a non-canonical FLT3 mutation: A proof of concept.
Br J Haematol. 2023;203:327-330.
PubMed

EADIE LN, Rehn JA, Schutz CE, Heatley SL, et al
Case report: Rare case of donor cell-derived T-cell acute lymphoblastic leukaemia in a female patient after receiving an allo-transplant from her male sibling.
Br J Haematol. 2023;203:282-287.
PubMed Abstract available

APOSTOLOVA P, Kreutmair S, Toffalori C, Punta M, et al
Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response.
Br J Haematol. 2023;203:264-281.
PubMed Abstract available

September 2023

BRECCIA M, Saglio G
Interferon in chronic myeloid leukaemia: Is it useful for treatment-free remission?
Br J Haematol. 2023;202:1087-1088.
PubMed Abstract available

HADDAD FG, Kourie HR, Saleh K
Moving away from chemotherapy in newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.
Br J Haematol. 2023;202:1084-1086.
PubMed Abstract available

IRANI YD, Hughes A, Kok CH, Clarson J, et al
Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha.
Br J Haematol. 2023;202:1127-1136.
PubMed Abstract available

FENG H, Fu Y, Cui Z, Zhou M, et al
Histone demethylase PHF8 facilitates the development of chronic myeloid leukaemia by directly targeting BCR::ABL1.
Br J Haematol. 2023;202:1178-1191.
PubMed Abstract available

PESCHKE JC, Bergmann R, Mehnert M, Gonzalez Soto KE, et al
FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia.
Br J Haematol. 2023;202:1137-1150.
PubMed Abstract available

PASTORE F, Gittinger H, Raab S, Tschuri S, et al
Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
Br J Haematol. 2023;202:1165-1177.
PubMed Abstract available

XIE M, Lu Y, Ouyang G, Li X, et al
Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
Br J Haematol. 2023;202:1119-1126.
PubMed Abstract available

MATSUMOTO K, Kakazu N, Imataki O, Kondo A, et al
Hairy cell leukaemia with an IGH-BRAF fusion gene.
Br J Haematol. 2023;202:e67-e70.
PubMed

BELHADJ M, Burroni B, Kosmider O, Willems L, et al
Clinico-biological features, treatment and prognosis of primary myeloid sarcoma: A French retrospective multi-centric observational study.
Br J Haematol. 2023;202:e50-e53.
PubMed

August 2023

KUSUDA M, Nakasone H, Yoshimura K, Okada Y, et al
Gene expression and TCR amino acid sequences selected by HLA-A02:01-restricted CTLs specific to HTLV-1 in ATL patients.
Br J Haematol. 2023;202:578-588.
PubMed Abstract available

LOKE J, Upasani V, Gaskell C, Fox S, et al
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromes.
Br J Haematol. 2023;202:498-503.
PubMed Abstract available

SARTOR C, Brunetti L, Audisio E, Cignetti A, et al
A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure.
Br J Haematol. 2023;202:599-607.
PubMed Abstract available

BORRILL R, Poulton K, Kusyk L, Routledge A, et al
Granulocyte transfusion during cord blood transplant for relapsed, refractory AML is associated with massive CD8(+) T-cell expansion, significant cytokine release syndrome and induction of disease remission.
Br J Haematol. 2023;202:589-598.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum